RUIDOSO DOWNS, NM – April 3, 2014 – Graduates of 2013 Ruidoso Select Yearling Sale – headed by Louis Howard’s fastest-qualifier First Famous Eagle – took three of the 10 qualifying spots to the Grade 1, $309,091 West Texas Futurity.
Also reaching the 300-yard finals on April 13 are sale graduates Bigtime Bye and Encore For James.
All three of these Ruidoso Select Yearling Sale graduates are eligible for the Grade 1, $700,000 Ruidoso Futurity; Grade 1, $900,000 Rainbow Futurity and the Grade 1, $2.6 All American Futurity this summer at Ruidoso Downs.
First Famous Effort, a gelding by One Famous Eagle from the First Down Dash daughter Tiny First Effort, won his trial by two-and-three-quarter lengths in his career debut. His time of :14.998 was the quickest mark from nine trials.
Consigned by the famed 6666 Ranches, a member of the Ruidoso Downs Racehorse Hall of Fame, First Famous Effort sold for $50,000 to Howard. His dam won the 2001 Grade 1 Southern California Derby and was named 2001 champion three-year-old filly. She is the dam of three stakes-placed performers
A gelding by Bigtime Favorite and out of Marcys Dashin Bye by Dashin Bye, Bigtime Bye took his West Texas Futurity trial by one-half length while stopping the timer in :15.261.
Bigtime Bye was purchased by La Feliz Montana Ranch LLC on a bid of $10,000 from the Grant Farms LLC consignment. He is a full brother to track-record-setter and Grade 1 Firecracker Futurity winner Big Dashing Perry.
Victor Lozano’s Encore For James, an Ivory James colt out of the Rare Form daughter Rare Encore, was a one-half-length trial winner and a $23,000 Ruidoso Select Yearling Sale purchase from the Tom Bradbury consignment. He was timed in :15.282.
Encore For James’ dam won the Cherry Creek Futurity and is the dam of one stakes winner and four stakes-placed runners.
This year’s Ruidoso Select Yearling Sale will be held on August 29-31.
The Ruidoso Downs summer racing season starts on May 22 with two days of trials to the 350-yard Ruidoso Futurity and these three horses are likely competitors in these trials.